GASTROINTESTINAL CANCER

Ripretinib for advanced gastrointestinal stromal tumours

A double-blind, randomized, placebo-controlled, phase III trial has shown that ripretinib (a switch-control tyrosine kinase inhibitor) markedly improves progression-free survival in patients with advanced gastrointestinal stromal tumours who were resistant to approved treatments. From across 29 specialized hospitals in 12 locations, 129 patients (>18 years old) were recruited and randomly assigned to receive either oral ripretinib 150 mg once daily (n = 85) or placebo once daily (n = 44). In the double-blind period, median progression-free survival was 6.3 months (95% CI 4.6–6.9) in the ripretinib group versus 1.0 month (95% CI 0.9–1.7) in the placebo group (hazard ratio 0.15, 95% CI 0.09–0.25; P < 0.0001). Ripretinib had an acceptable safety profile, with the most common grade 3 or 4 treatment-emergent adverse events including, among others, hypertension and fatigue in the ripretinib group.

References

Original article

  1. Blay, J.-Y. et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30168-6 (2020)

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Katrina Ray.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ray, K. Ripretinib for advanced gastrointestinal stromal tumours. Nat Rev Gastroenterol Hepatol 17, 452 (2020). https://doi.org/10.1038/s41575-020-0336-2

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing